Based on the treatment outcomes with GIP/GLP-1 dual agonist, we might explore other combinations, such as a triagonistGLP/GIP/glucagon or other dual agonists involving glucagon, which are currently under development
Currently, the plan covers GLP-1 drugs for diabetes treatment but not for obesity
This package includes physician evaluations, follow-up consultations, unlimited clinician access, monthly prescriptions,and a 4-week or a 12-week supply of medication (based on the plan that you choose)
Furthermore, this hormone inhibits gastric emptying, gastrointestinal motility, and glucagon secretion [9,10,11]
Patient Care Coordinators are responsible for contacting potential patients, scheduling appointments and resolving patient issues
Secondary outcomes included change in arterial lactate, SOFA score, PaO2/FiO2 ratio, and 14 and 28-day mortality